Meanwhile, investors await key clinical data.
ApexOnco Front Page
Recent articles
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
Skyscraper-06 blows up spectacularly, and that’s bad news for Skyscraper-01.
A three-way race is on to determine which Car-T therapy Gilead will take into pivotal trials.
Two anti-TROP2 ADCs join cell therapies and Teva’s anti-PD-1 in first-in-human studies.
After being burned by Point, Lilly is taking a slower approach with Radionetics.